Clinical Trial Update: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Azeliragon (TTP488) for mild Alzheimer's disease was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Azeliragon (Azeliragon)

Snippet

Sponsor: vTv Therapeutics | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-05-07